The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

AQI levels in Delhi crossed 400, in the severe category, on Tuesday, with several monitoring stations in the 'severe plus' ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

A 21-year-old engineering student from Delhi, suffering from severe allergic asthma and rashes, successfully underwent personalised treatment in Hyderabad. Combining immunotherapy, probiotics and ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Garda Joseph Joyce, who has been on the force since 2000, has alleged disability discrimination, harassment and victimisation ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...